While most evidence suggests they are also clinically resistant to tamoxifen and fulvestrant/ICI4, 8, 9, recent studies demonstrated increased prevalence of ERα mutations in breast cancers of patients treated with aromatase inhibitors, but not in patients treated with fulvestrant5, or tamoxifen6. This evidence concerns the gene CYP19A1 and breast carcinoma.